Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.




上海復星醫藥(集團)股份有限公司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)


(Stock Code: 02196)

2015 THIRD QUARTERLY REPORT



B O B T Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* Chen Qiyu

Chairman



As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

* for identification purposes only


1. IMPORTANT NOTICE

- Committee"). C ("Board") d ("Supervisory ("S
- 1.2 A $\frac{1}{2}$ $\frac{1}{2}$
- 1.4 \mathcal{C}_{i} \mathcal{C}_{i} \mathcal{C}_{i} \mathcal{C}_{i} \mathcal{C}_{i} \mathcal{C}_{i}

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

2.1	M	. "	•	- 1 ₀₀	

200		. : .	C_t : MB
	As at the end of the Reporting Period (30 September 2015)	previous year	Change recorded at the end of the Reporting Period compared(th)5.red6.1121 Reeri4mber-13.4(2)6.9(014






Items	Amounts during the Reporting Period (Jul – Sep 2015)	Amounts from the beginning of the year to the end of the Reporting Period (Jan - Sep 2014)	Description
P	97,665,175.84	191,310,773.56	M to G.




I was a second						73,142
The	shareholding s	tatus of the T	op 10 sharehol	ders		
	Shareholding at the end of	Percentage	Number of restricted	Shares pl locke	_	Capacity
Name of shareholders (full name)	the period	(%)	shares held	Status	Number	
HANGHAI FO N HIGH CECHNOLOG (G O) COM AN LIMI ED ("F (G ("))	920,641,314	39.83	0	N.,	0	D. h.
HK CC NOMINEE LIME ED (N 1)	402,619,300	17.42	0		0	
CHINA EC L'IE FINANCE CO LO ALION LIMB ED	69,112,399	2.99	0	Ν.,	0	* ** *
NA IONAL OCIAL EC E F ND 104 O FOLIO*	37,199,998	1.61	0	Ν.,	0	* ** *
HONG KONG EC LIE CLEA ING COMPAN LIMB ED (N 2)	33,556,005	1.45	0	Ν.,	0	
CEN AL H IJIN IN F MEN L D.	24,067,700	1.04	0	N.,	0	
INH A LIFE IN ANCE CQ., L. D. — DI → DEND — G Q → DI → DEND — 018L — FH001 HANGHAI*	22,652,864	0.98	0	N.,	0	
ING CAP AL (BEIJING) CO., L'D ING CAP AL G O H F ND NO. I*	17,695,247	0.77	0	N.,	0	
FO IC ING ELEC ED 1*	16,764,537	0.73	0	Ν.,	0	* ** *
NNG AN COLD — ELLE E IN F MEN ING CAM AL	16,567,783	0.72	0	Ν.,	0	· · · ·

The shareholding status	s of the Top 10 unrestric	ted shareholders	
	Number of	Type and num	ber of shares
	unrestricted tradable		
Name of the shareholders	shares held	Type	Number
F 1. G. 1	920,641,314	MB.	920,641,314
HK CC NOMINEE LIMB ED (Note 1)	402,619,300	6	402,619,300
CHINA EC L'IE FINANCE CO LO ALION LIMI ED	69,112,399	MB.	69,112,399
NA LONAL OCIAL EC B F ND 104	37,199,998	MB.	37,199,998
HONG KONG EC BIE CLEA ING COMPAN LIMB ED (Note 2)	33,556,005	MB.	33,556,005
CEN AL H IJIN IN F MEN L D.	24,067,700	MB.	24,067,700
INH A LIFE IN ANCE CQ., L'D. — DI → DEND — GQ → DI → DEND — 018L — FH001 HANGHAI*	22,652,864	MB.	22,652,864
ING CAR AL (BEIJING) CO., L'D — ING CAR AL GO, H F ND NO. I*	17,695,247	MB.	17,695,247
FO IC FING ELEC ED 1*	16,764,537	MB.	16,764,537
MNG AN CO., L'D — ELLE E IN MEN ING CAN AL	16,567,783	MB. A.	16,567,783
D, t , , , , , , , , , , , , , , , ,	G Q H F ND NQ. AN CQ., L D CQ., L D	BEIJING) CO, L'D — I*, FO IC ING E ELL E IN E MEN ING CAP AL (BE	LECSED 1* 🚅 JING
D, t in the transfer of the tr	N • · •		



3. SIGNIFICANT EVENTS



		Balance Sl	heet	
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons
Q ~ ~ ~ ~ ~	485,549,599.95	198,755,576.52	144.29%	M to the second
A		990,340,787.62	-100.00%	(N ,)
Q , 16 ,	3,494,730.03	11,246,964.92	-68.93%	Man to a second to
A • • • • • • • • • • • • • • • • • • •	3,529,897,004.62	2,499,156,438.67	41.24%	M
Dan Jan and La	167,214,321.23	89,379,481.02	87.08%	Maria &D. A. Maria
m	4,508,065,870.77	2,841,223,392.47	58.67%	Ma the special and the second
³ 44 .	474,418,367.92	342,926,461.15	38.34%	Marian Marian
D 1,	14,831,357.70	1,279,819.25	1,058.86%	M
L		589,118,424.34	-100.00%	(N ,)
N. Ti a.	2,822,255,623.13	1,109,525,523.85	154.37%	M
Q , 16 ,	63,116,411.43	1,070,561,681.96	-94.10%	M
r. 1 - 1 1 - 1	1,618,247,844.35	771,191,646.56	109.84%	Marian Araban and Start A
B. / •	1,894,480,886.28	3,085,482,735.30	-38.60%	Maria de la companya della companya

	Income Statement								
	Current amount	Amount of the last period							
Items	Jan - Sep 2015	Jan - Sep 2014	Ratio of change	Reasons					
F. •1.	339,686,256.62	251,024,209.33	35.32%	M to the second					
A ~ ½ ¶½ ~ ~ ~	33,340,027.70	11,784,007.60	182.93%	Marie and the second second					
G In	3,506,487.53	-9,516,778.44	136.85%						
N. = , • 1 ,	63,499,502.52	38,512,060.43	64.88%	Maria de la companya					
N. : , • 1	10,862,409.73	15,531,263.99	-30.06%	Market State of the State of th					
Q ~ 1- 120 ~ ~ ~ ~ ~ 1- 120°	-279,141,519.38	146,057,212.28	-291.12%	Maria de la companya del companya de la companya de la companya del companya de la companya de l					

Statement of Cash Flow								
	Current amount	Amount of the last period						
Items	Jan - Sep 2015	Jan - Sep 2014	Ratio of change	Reasons				
N I	1,161,951,526.99	843,637,595.71	37.73%	Maria de la constanta de la co				
N, I	764,402,303.12	1,793,987,740.16	-57.39%	M 2014 G G (

- - © 10 2015, C h 2015 MB400 h 2015.

(3) Q 16 A 20 B (C C C M A C C C L C A C C C C C C C C C C C C C	C L T (M)	C ., L .* (招 (泰康資產管理有阿 理有限公司), C 可限公司), A . 有限公司), B	$\begin{array}{cccccccccccccccccccccccccccccccccccc$
MB3,600,000,	1 A _i 2015, 249,784,664	2014 i ha	MB5,799,999,985
B C	2015, 2015 (1) 2015 (1) ,024,978 989.16.	har i	
1 2 - 2	C C.		MB5

Pr.		1	26.	1		
Background	Туре	Covenantors	Undertakings	Validity period	Whether duration specified	Whether timely and
Duengivunu	- J pc	Corenanions	Chuci tunings	randity period	specificu	



Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

L
29 2015

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2015

: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

	:	ι	C_{l}	a. 1	:	MB	ļ	A *	_ /	:		-d	d
*	٠	,	υı	~ -	•	1,12	-	~ ~		•	7	ľ	~ "

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Ca at a aa,	3,516,813,404.78	3,695,698,185.82
L. T		
E:	38,724,495.54	33,770,584.14
B of a	408,527,911.80	472,523,132.7
	1,789,464,377.02	1,504,149,790.7
Pr The Property of the Propert	136,605,468.61	137,690,114.0
Part Table ala		
ar library and ala		
I can ala Ta	677,257.70	1,023,889.42
D fact ata Ta	16,983,973.47	14,264,402.90
	485,549,599.95	198,755,576.5
MI TO THE STATE OF		
	1,627,321,198.79	1,604,562,390.23
A,		990,340,787.62
Note to the second		
Q , 16 ,	3,494,730.03	11,246,964.92
le The To	8,024,162,417.69	8,664,025,819.13
Non-current assets:		
Programme to the second		
A • • • • • • • • • • • • • • • • • • •	3,529,897,004.62	2,499,156,438.6
H, #		
L ₁ - 20		
L. 1- m	13,489,435,775.47	11,905,750,117.5
I 200 200		
F , T	4,720,292,409.25	4,623,958,317.63
C. v	964,172,888.14	1,051,988,109.5
P. A. C.	3,233,982.94	5,450,698.63
D		
Policy of the state of the stat		
<u> </u>		
Ţ ¶, , ¶,	2,857,317,020.41	2,822,483,093.20
Do not have a set to	167,214,321.23	89,379,481.02
G. d. m	3,292,538,591.11	3,255,041,739.55
Let- alian ala pella	11,804,369.09	13,583,440.83
D. A. A. M.	92,366,614.48	101,221,671.79
Q , 71 ,. T	262,125,551.28	304,238,328.42
e Ten The production	29,390,398,528.02	26,672,251,436.83
	37,414,560,945.71	35,336,277,255.96

Consolidated balance sheet (Continued)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:	1 1111	
	4,508,065,870.77	2,841,223,392.47
B. T. I. A. A. A.		
D		
La ., " L.		
F. w w		
В	67,928,606.53	70,987,451.05
4. 44.	874,465,599.33	833,974,948.21
	226,002,022.22	266,518,255.34
Gu., J. J. L.		
F _A	207, 007, 720, 40	200 472 746 11
	296,895,628.48	298,472,746.11
) ¶ ¶,	474,418,367.92 166,803,873.32	342,926,461.15 177,075,081.31
D A A	14,831,357.70	1,279,819.25
ν τ _λ , τ	1,379,103,280.44	1,935,656,885.83
	1,379,103,280.44	1,933,030,663.63
I		
A ,		
AM		
L		589,118,424.34
N. 1/	2,822,255,623.13	1,109,525,523.85
0 . 16	63,116,411.43	1,070,561,681.96
	10,893,886,641.27	9,537,320,670.87
Non-current liabilities:		
L	1,618,247,844.35	771,191,646.56
B. A.	1,894,480,886.28	3,085,482,735.30
L, -, .	890,883,419.71	710,056,624.65
An in the second		
D	178,123,561.73	139,593,190.51
D, A A	1,934,427,964.42	1,929,331,107.42
Questin Time	73,391,869.13	60,299,392.99
Profession 1 pr	6,589,555,545.62	6,695,954,697.43
7. 4	17,483,442,186.89	16,233,275,368.30
Equity:	2 211 200 264 00	2 211 (11 2(4 00
	2,311,380,364.00 6,049,708,237.59	2,311,611,364.00 6,123,454,191.14
	0,049,708,237.39	0,123,434,191.14
<u>L</u> , . ,	+	
0 1	838,468,407.81	1,120,365,125.73
	1,662,373,054.64	1,662,373,054.64
G	1,002,373,034.04	1,002,373,034.04
- · · ·	6,700,890,376.05	5,457,045,050.64
Earlean	0,700,070,370.03	3, 137,073,030.07
The problem of the second of the leg	17,562,820,440.09	16,674,848,786.15
N. T	2,368,298,318.73	2,428,153,101.51
	19,931,118,758.82	19,103,001,887.66
	37,414,560,945.71	35,336,277,255.96

Legal Representative:


Chief Financial Officer:

Director of the Accounting Department:

Chen Qiyu

Guan Xiaohui

Yan Jia



Balance Sheet of the Parent Company (Continued)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
	1,834,226,000.00	
F. T. T.		
В		
مام المام الم		
44. 44.	78,632,661.11	72,568,579.44
	23,932,653.33	21,842,286.49
I co	147,159,729.00	160,716,398.26
D In I	1,364,923.50	1,062,450.00
0	453,068,674.16	587,606,051.26
N. Ti ar	2,641,935,028.99	1,037,216,423.85
Quite a		998,894,520.55
- 16 pr	5,180,319,670.09	2,879,906,709.85
Non-current liabilities:		
L.,-,,	186,740,000.00	85,000,000.00
B	1,894,480,886.28	3,085,482,735.30
L., Table		
An int		
Dan all state	1,525,000.00	1,750,000.00
D	1,209,260,573.79	1,192,857,263.79
Q , 76 ,		
a Terration The A	3,292,006,460.07	4,365,089,999.09
	8,472,326,130.16	7,244,996,708.94
Equity:		
	2,311,380,364.00	2,311,611,364.00
C	8,227,835,906.44	8,270,816,715.22
L : • •		
Q o let o o e let o	55,747,958.04	224,689,817.57
1 1 20	949,985,460.52	949,985,460.52
G., •		
	4,193,926,575.18	2,839,595,396.66
3.	15,738,876,264.18	14,596,698,753.97
	24,211,202,394.34	21,841,695,462.91

Legal Representative: Chen Qiyu

Chief Financial Officer:

Director of the Accounting Department:

Yan Jia

Guan Xiaohui

Consolidated Income Statement

January – September 2015

P. 4

: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

				3	,	r		1			1	1
*	:	$\iota \blacksquare C_{\iota}$	A- 1	:	MB	5	* *	4	:	-	4	الم م

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I.	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
In the section	3,152,113,519.72	3,122,905,282.64	9,073,497,568.10	8,661,444,631.29
I				
Em				
E. Maria				
II.	2,895,782,154.22	2,841,148,358.80	8,300,064,068.03	8,033,810,333.58
In the state of th	1,549,543,653.59	1,718,871,717.37	4,479,008,803.33	4,905,488,021.73
I and a second	1,517,515,055.57	1,710,071,717.37	1,179,000,003.33	1,703,100,021.73
F. Strand				
200200 :				
Mark Comments				
C				
N, 200				
ما الما ا				
* * * * * * * * * * * * * * * * * * *				
A _{not}				
B _i	24,497,548.36	23,567,831.20	74,510,036.45	59,883,149.42
_4 4	752,785,285.93	589,494,712.71	2,033,469,048.98	1,606,792,320.56
A	439,321,906.97	417,425,034.77	1,340,049,894.95	1,198,838,624.94
F	118,030,107.88	91,347,934.22	339,686,256.62	251,024,209.33
	11,603,651.49	441,128.53	33,340,027.70	11,784,007.60
A	11,005,031.49	441,126.33	33,340,027.70	11,784,007.00
≯ι: G Im' In'				
-				

Consolidated Income Statement (*Continued***)**

January – September 2015

	Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
_	Q a lega a collega	-503,674,636.21	170,383,244.67	-279,141,519.38	146,057,212.28
	2	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
	2.				
		-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
	1.	732,427.55	-9,352.18	-195,739,333.69	-5,108,705.95
	2. C 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	-440,970,255.91	171,599,596.74	-16,216,735.14	149,088,050.35
	3. G				
	4. E , , , , , , , , , , , , , , , , , ,				
	5. E. I. A.	-65,806,450.80	-1,851,673.11	-69,940,649.09	3,828,899.96
		2,369,642.95	644,673.22	2,755,198.54	-1,751,032.08
⊅ ¥I.	The control of the co	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
	Veg	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
		75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
J#II	. Eq. , :				
	(1)	0.25	0.24	0.82	0.69
	(2)	0.25	0.24	0.82	0.69

Legal Representative:

Chief Financial Officer: Director of the Accounting Department:

Chen Qiyu

Guan Xiaohui

Yan Jia

Consolidated Statement of Cash Flow

January – September 2015



Consolidated Statement of Cash Flow (Continued)

January – September 2015

	Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III.	Cash flow generated from financing activities:		
	C 12 21 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2	87,721,195.00	1,445,949,451.00
	In the property of the second	87,721,195.00	38,269,850.07
	C 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	5,110,056,682.54	3,475,109,758.30
	Con all transfer to the contract of the contra	398,929,000.00	1,000,000,000.00
		40,140,014.05	21,733,509.09
	to the New York Not of the New York	5,636,846,891.59	5,942,792,718.39
	C	3,519,139,442.58	1,623,242,732.68
	Con the state of t	1,114,614,719.91	1,012,768,967.52
	In the state of the second second second	268,686,768.21	133,554,721.22
	Q A THE A PAIR OF THE A	238,690,425.98	1,512,793,278.03
	to the termination of the termin	4,872,444,588.47	4,148,804,978.23
	N 1	764,402,303.12	1,793,987,740.16
IV.	Effects of exchange rate fluctuations on cash and cash equivalents	5,949,548.99	14,780,312.38
V.	Net increase of cash and cash equivalents	28,667,545. % 1	8

Statement of Cash Flow of the Parent Company

January – September 2015

: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

$\vdots C_{l} \cdots MB \qquad \qquad \blacksquare \qquad \vdots \qquad \blacksquare$	*	:	$\iota \blacksquare C_{\iota}$	a- 1	:	MB	ţ	<i>~</i> *	_ d	:		ا ا
--	---	---	--------------------------------	------	---	----	---	------------	------------	---	--	-----

Items I. Cash flow generated from operating activities:	Current Amount (January – September)	Amount of the Last Period (January – September)
1. Cash now generated from operating activities:	450,000,00	450,000,00
Carlo al anticolor anticol	450,000.00	450,000.00
a let e		